Cargando…

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation

BACKGROUND: The correct valganciclovir dose for cytomegalovirus (CMV) prophylaxis depends on renal function estimated by the Cockcroft–Gault (CG) estimated creatinine clearance (CG-CrCl) formula. Patients with delayed or rapidly changing graft function after transplantation (tx) will need dose adjus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rissling, Olesja, Naik, Marcel, Brakemeier, Susanne, Schmidt, Danilo, Staeck, Oliver, Hohberger, Arnim, Neumayer, Hans-Hellmut, Budde, Klemens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070081/ https://www.ncbi.nlm.nih.gov/pubmed/30094022 http://dx.doi.org/10.1093/ckj/sfx145

Ejemplares similares

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2019)

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
por: Kabata, Yoshiaki, et al.
Publicado: (2012)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
por: Patil, A Jayaprakash, et al.
Publicado: (2010)

Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB
por: Clerici, Daniela, et al.
Publicado: (2022)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease
por: Akahoshi, Yu, et al.
Publicado: (2022)

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation
por: Li, Po-Hsien, et al.
Publicado: (2021)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

Analysis of Risk Factors and Long-Term Outcomes in Kidney Transplant Patients with Identified Lymphoceles
por: Lehner, Lukas J., et al.
Publicado: (2020)

Evaluating a Change in Surgical Antibiotic Prophylaxis in Kidney Transplant Recipients
por: Bliven, Katherine, et al.
Publicado: (2018)

1146. Thrombocytosis in Infants with Congenital Cytomegalovirus Infection Being Treated with Valganciclovir
por: Murtagh, Kathleen, et al.
Publicado: (2020)

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant
por: Rubinstein, Jeremy D., et al.
Publicado: (2022)

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
por: Ueda Oshima, Masumi, et al.
Publicado: (2023)

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir
por: Ortiz-Gracia, Alba, et al.
Publicado: (2022)

LB2307. Safety and Efficacy of Letermovir (LET) versus Valganciclovir (VGCV) for Prevention of Cytomegalovirus (CMV) Disease in Kidney Transplant Recipients (KTRs): A Phase 3 Randomized Study
por: Limaye, Ajit P, et al.
Publicado: (2022)

Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment
por: Torii, Yuka, et al.
Publicado: (2023)

Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series
por: Osmanodja, Bilgin, et al.
Publicado: (2021)

Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10
por: Mayer, Katharina A., et al.
Publicado: (2022)

Cytokine and Chemokine Secretome and Risk of CMV Infection Following Discontinuation of Valganciclovir Prophylaxis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2023)

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft-versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplant: A Single Institution Experience
por: Hashmi, Hamza, et al.
Publicado: (2020)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014)

Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection
por: Waiser, Johannes, et al.
Publicado: (2016)

Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial
por: Reischig, Tomas, et al.
Publicado: (2018)

Human Cytomegalovirus Infection Enhances NK Cell Activity In Vitro
por: Tschan-Plessl, Astrid, et al.
Publicado: (2016)

Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction
por: Bennett, David, et al.
Publicado: (2022)

Detection of overdose and underdose prescriptions—An unsupervised machine learning approach
por: Nagata, Kenichiro, et al.
Publicado: (2021)

Persistent Underdosing of Benzodiazepines for Status Epilepticus: The Weight Is the Hardest Part
por: Noe, Katherine
Publicado: (2021)

Explicit underdose control based on toxicity: Four points to consider
por: Frankel, Paul H., et al.
Publicado: (2022)

Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
por: Johansson, Inger, et al.
Publicado: (2013)

Cytomegalovirus Immunity Assays Predict Viremia but not Replication Within the Lung Allograft
por: Li, Jenny, et al.
Publicado: (2023)

Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and Efficacy
por: Kalil, Andre C., et al.
Publicado: (2009)

Long-term results of oral valganciclovir for treatment of anterior segment inflammation secondary to cytomegalovirus infection
por: Wong, Victoria WY, et al.
Publicado: (2012)

Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection
por: Ohyama, Shohei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_omm44aau9j0bm533sk3b0gmc9f